Since both CYP3A4 and A9 metabolize SF and are expressed in the kidney31–33,35,37,38, we investigated if their expression, and consequently, SF metabolism are altered in RCC cells treated with the SF and MU combination (SF + MU). Here, IGKV1D-22 is linked to renal cell carcinoma.